Chlamydia control: A comparative review from the USA and UK

The New Public Health and STD/HIV Prevention: Personal, Public and Health Systems Approaches

Volumn , Issue , 2013, Pages 401-430

  Low, Nicola ^a   Geisler, William M ^b   Stephenson, Judith M ^c   Hook, Edward W ^b,d  

^a UNIVERSITY OF BERN   (Switzerland)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Jefferson County Department of Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84894086996     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4526-5_20     Document Type: Chapter

References (152)

1. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2009. Atlanta: U.S. Department of Health and Human Services; 2010.
2. Fenton KA, Korovessis C, Johnson AM, et al. Sexualbehaviour in Britain: reported sexually transmittedinfections and prevalent genitalChlamydia trachomatisinfection. Lancet. 2001;358:1851-4.
3. Datta SD, Sternberg M, Johnson RE, et al. Gonorrheaand chlamydia in the United States among persons14 to 39 years of age, 1999 to 2002. Ann Intern Med.2007; 147(2): 89-96.
4. World Health Organization. Global prevalence andincidence of selected curable sexually transmittedinfections. Overview and estimates. Geneva: WorldHealth Organisation; 2001.
5. Cates Jr W, Rolfs Jr RT, Aral SO. Sexually transmitted diseases, pelvic inflammatory disease, and infertility: an epidemiologic update. Epidemiol Rev.1990;12:199-220.
6. Mardh PA, Ripa T, Svensson L, Westrom L.Chlamydiatrachomatisinfection in patients with acute salpingitis.N Engl J Med. 1977;296(24):1377-9.
7. Westrom L. Effect of acute pelvic inflammatorydisease on fertility. Am J Obstet Gynecol. 1975;121(5):707-13.
8. Svensson L, Mardh PA, Westrom L. Infertility afteracute salpingitis with special reference toChlamydiatrachomatis.Fertil Steril. 1983;40(3):322-9.
9. Washington AE, Katz P. Ectopic pregnancy in theUnited States: economic consequences and paymentsource trends. Obstet Gynecol. 1993;81(2):287-92.
10. Washington AE, Arno PS, Brooks MA. The economic cost of pelvic inflammatory disease. Jama. 1986;255(13): 1735-8.
11. Washington AE, Cates WJ, Wasserheit JN.Preventing pelvic inflammatory disease. Jama.1991;266(18):2574-80.
12. Low N. Screening programmes for chlamydial infection: when will we ever learn? BMJ. 2007;334(7596):725-8.
13. Berridge V. Aids in the UK: the making of Policy,1981-1994. Oxford: Oxford University Press; 1996.
14. Ripa T. Epidemiologic control of genitalChlamydiatrachomatisinfections. Scand J Infect Dis Suppl.1990;69:157-67.
15. Herrmann BF, Johansson AB, Mardh PA. A retrospective study of efforts to diagnose infections byChlamydia trachomatisin a Swedish county. Sextransm Dis. 1991;18(4):233-7.
16. Addiss D, Vaughin ML, Ludka D, Pfister J, Davis JP.Decreased prevalence ofChlamydia trachomatisinfection associated with a selective screening program in family planning clinics in Wisconsin. Sextransm Dis. 1993;20:28-34.
17. Nicoll A, Hughes G, Donnelly M, et al. Assessingthe impact of national anti-HIV sexual health campaigns: trends in the transmission of HIV and othersexually transmitted infections in England. Sextransm Infect. 2001;77(4):242-7.
18. Coutinho RA, Rijsdijk AJ, van den Hoek JA, Leentvaar-Kuijpers A. Decreasing incidence ofPID in Amsterdam. Genitourin Med. 1992;68(6):353-5.
19. U.S. Preventive Services Task Force. Screening forchlamydial infection: U.S. Preventive Services TaskForce recommendation statement. Ann Intern Med.2007;147:128-34.
20. Centers for Disease Control and Prevention. Sexuallytransmitted diseases treatment guidelines, 2010.MMWR Recomm Rep. 2010; 59(RR-12); 44-5.
21. Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. Melbourne: RACGP; 2007.
22. Department of Health. National ChlamydiaScreening Programme (NCSP) in England: programme overview; core requirements; data collection. 2Nd ed. London: Department of Health; 2004.http://www.dh.gov.uk/assetRoot/04/09/26/48/04092648.pdf. Accessed 6 Sep 2012.
23. Low N, Bender N, Nartey L, Shang A, StephensonJM. Effectiveness of chlamydia screening: systematic review. Int J Epidemiol. 2009;38(2):435-48.
24. Gottlieb SL, Berman SM, Low N. Screening and treatment to prevent sequelae in women withChlamydiatrachomatisgenital infection: how much do we know?J Infect Dis. 2010;201 Suppl 2:S156-67.
25. Hay PE, Pittrof RU. Has the effectiveness of a singlechlamydia test in preventing pelvic inflammatorydisease over 12 months been overestimated? WomensHealth (Lond Engl). 2010;6(5):627-30.
26. Stamm WE.Chlamydia trachomatisinfections ofthe adult. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, et al., editors.Sexually transmitted diseases. 4Th ed. New York:McGraw Hill Medical; 2008. P. 575-93.
27. Geisler WM. Duration of untreated, uncomplicatedChlamydia trachomatisgenital infection and factorsassociated with chlamydia resolution: a review ofhuman studies. J Infect Dis. 2010;201(S2):104-13.
28. Batteiger BE, Xu F, Johnson RE, Rekart ML.Protective immunity toChlamydia trachomatisgenital infection: evidence from human studies. J InfectDis. 2010;201 Suppl 2:S178-89.
29. Paavonen J, Westrom L, Eschenbach D. Chapter 56.Pelvic inflammatory disease. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, et al., editors. Sexually transmitted diseases. 4Th ed. New York: McGraw Hill Medical;2008. P. 1017-50.
30. Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae afterChlamydia trachomatisgenital infection in women. J Infect Dis.2010;201 Suppl 2:S134-55.
31. van Valkengoed IG, Morre SA, van den Brule AJ, Meijer CJ, Bouter LM, Boeke AJ. Overestimation ofcomplication rates in evaluations ofChlamydia trachomatisscreening programmes#x2014;implications forcost-effectiveness analyses. Int J Epidemiol.2004;33(2):416-25.
32. Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook III EW. The natural history ofuntreatedChlamydia trachomatisinfection in theinterval between screening and returning for treatment. Sex Transm Dis. 2008;35(2):119-23.
33. Hook III EW, Spitters C, Reichart CA, NeumannTM, Quinn TC. Use of cell culture and a rapid diagnostic assay forChlamydia trachomatisscreening.JAMA. 1994;272(11):867-70.
34. Wein P, Kloss M, Garland SM. Postabortal pelvicsepsis in association withChlamydia trachomatis.Aust N Z J Obstet Gynaecol. 1990;30(4):347-50.
35. Qvigstad E, Skaug K, Jerve F. Pelvic in fl ammatorydisease associated withChlamydia trachomatisinfection after therapeutic abortion. A prospectivestudy. Br J Vener Dis. 1983;59(3):189-92.
36. Rice PA, Schachter J. Pathogenesis of pelvicin fl ammatory disease. What are the questions?JAMA. 1991;266(18):2587-93.
37. Westrom L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility. A cohort study of 1, 844 women with laparo-scopically verified disease and 657 control womenwith normal laparoscopic results. Sex Transm Dis.1992;19(4):185-92.
38. Westrom L. Pelvic inflammatory disease. Jama.1991;266(18):2612.
39. Wasserheit JN, Aral SO. The dynamic topology ofsexually transmitted disease epidemics: implicationsfor prevention strategies. J Infect Dis. 1996;174Suppl 2:S201-13.
40. Garnett GP. The geographical and temporal evolution of sexually transmitted disease epidemics. Sextransm Infect. 2002;78 Suppl 1:14-9.
41. Miller WC, Ford CA, Morris M, et al. Prevalence ofchlamydial and gonococcal infections among youngadults in the United States. Jama. 2004;291(18):2229-36.
42. Hosenfeld CB, Workowski KA, Berman S, et al.Repeat infection with Chlamydia and gonorrheaamong females: a systematic review of the literature.Sex Transm Dis. 2009;36(8):478-89.
43. Gordon FB, Quan AL. Isolation of the trachomaagent in cell culture. Proc Soc Exp Biol Med.1965;118:354-9.
44. Johnson RE, Newhall WJ, Papp JR, et al. Screeningtests to detectChlamydia trachomatisandNeisseriagonorrhoeaeinfections#x2014;2002. Mmwr RecommRep. 2002;51(RR-15):1-38.
45. Health Protection Agency. Sti annual data tables(Topics, Sexually transmitted infections, disease statistics and surveillance).http://www.hpa.org.uk/web/HPAwebamp;HPAwebStandard/HPAweb_C/1203348026613. Accessed 6 Sep 2012.
46. Miller WC. Epidemiology of chlamydial infection:are we losing ground? Sex Transm Infect. 2008;84(2):82-6.
47. Low N. Caution: chlamydia surveillance data ahead.Sex Transm Infect. 2008;84(2):80-1.
48. Centers for Disease Control and Prevention. Sexuallytransmitted disease surveillance 2007 supplement, Chlamydia Prevalence Monitoring Project. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2009.
49. Last JM. A dictionary of epidemiology. Oxford:Oxford University Press; 2001.
50. Low N, Sterne JA, Barlow D. Inequalities in rates ofgonorrhoea and chlamydia between Black ethnicgroups in South East London: cross-sectional study.Sex Transm Infect. 2001;77:15-20.
51. Simms I, Talebi A, Riha J, et al. The English NationalChlamydia Screening Programme: variations inpositivity in 2007/2008. Sex Transm Dis. 2009;36(8):522-7.
52. Datta SD, Torrone E, Kruszon-Moran D, et al.Chlamydia trachomatistrends in the United Statesamong persons 14 to 39 years of age, 1999-2008.Sex Transm Dis. 2011;39(2):92-6.
53. Health Protection Agency. National ChlamydiaScreening Programme. Ncsp: five years. The fifthannual report of the National Chlamydia ScreeningProgramme 2007/8. London: Health ProtectionAgency; 2008.
54. World Health Organization. Icd-10. Internationalstatistical classification of diseases and related healthproblems. Tenth Revisionth ed. Geneva: WorldHealth Organization; 1992.
55. French CE, Hughes G, Nicholson A, et al. Estimationof the rate of pelvic inflammatory disease diagnoses:trends in England, 2000-2008. Sex Transm Dis.2011;38(3):158-62.
56. Simms I, Warburton F, Westrom L. Diagnosis ofpelvic inflammatory disease: time for a rethink. Sextransm Infect. 2003;79(6):491-4.
57. Chen MY, Fairley CK, Donovan B. Discordancebetween trends in chlamydia notifications and hospital admission rates for chlamydia related diseases inNew South Wales, Australia. Sex Transm Infect.2005;81(4):318-22.
58. Chen MY, Pan Y, Britt H, Donovan B. Trends in clinical encounters for pelvic inflammatory disease andepididymitis in a national sample of Australian general practices. Int J STD AIDS. 2006;17(6):384-6.
59. Westrom L. Decrease in incidence of women treatedin hospital for acute salpingitis in Sweden. Genitourinmed. 1988;64(1):59-63.
60. Bjartling C. Osser S, Persson K. The frequency ofsalping it is and ectopic pregnancy as epidermiologi-cal markers ofChlamydia trachomatisActa ObstctGynew/Scand 2000;79(2):123-8.
61. Centers for Disease Control and Prevention. Sexuallytransmitted disease surveillance 2008. Atlanta: U.S.Department of Health and Human Services, Centersfor Disease Control and Prevention; 2009.
62. Eschenbach DA, Buchanan TM, Pollock HM, et al.Polymicrobial etiology of acute pelvic inflammatorydisease. N Engl J Med. 1975;293(4):166-71.
63. Morgan J, Colonne C, Bell A. Trends of chlamydiainfection and related complications in New Zealand,1998-2008. Sex Health. 2011;8:412-8.
64. Bender N, Herrmann B, Andersen B, et al. Chlamydiainfection, pelvic inflammatory disease, ectopic pregnancy and infertility: cross-national study. Sextransm Infect. 2011;87(7):601-8.
65. Parran T. Shadow on the land#x2014;syphilis. New York:Reynal amp; Hitchcock; 1937.
66. Parran T. The eradication of syphilis as a practicalpublic health objective. Jama. 1931;97(2):73-7.
67. Low N, Broutet N, Adu-Sarkodie Y, Barton P, HossainM, Hawkes S. Global control of sexually transmittedinfections. Lancet. 2006;368(9551):2001-16.
68. Gray JA. New concepts in screening. Br J Gen Pract.2004;54(501):292-8.
69. Raffle A, Gray M. Screening: evidence and practice.Oxford: Oxford University Press; 2007.
70. Department of Health. Uk Screening Portal. Uknational Screening Committee. Programmeappraisal criteria.http://www.screening.nhs.uk/cri-teria. Accessed 6 Sept 2012.
71. National Health Committee. Screening to improvehealth in New Zealand. Criteria to assess screeningprogrammes.http://www.nhc.govt.nz/publications/PDFs/ScreeningCriteria.pdf. Accessed 20 Oct 2011.
72. Department of Health. Cmo#x2019;s Expert AdvisoryGroup onChlamydia trachomatis.London:Department of Health; 1998.
73. Stephenson JM. Screening for genital chlamydialinfection. Br Med Bull. 1998;54(4):891-902.
74. Low N, McCarthy A, Macleod J, et al.Epidemiological, social, diagnostic and economicevaluation of population screening for genital chlamydial infection. Health Technol Assess. 2007;11 (8): 1#x2014;184.
75. Harris RP, Helfand M, Woolf SH, et al. Currentmethods of the US Preventive Services Task Force:a review of the process. Am J Prev Med. 2001;20(3Suppl):21-35.
76. Miller WC. Screening for chlamydial infection: arewe doing enough? Lancet. 2005;365(9458):456-8.
77. LaMontagne DS, Fenton KA, Randall S, AndersonS, Carter P, on behalf of the National ChlamydiaScreening Steering Group. Establishing the NationalChlamydia Screening Programme in England: resultsfrom the first full year of screening. Sex TransmInfect 2004;80(5):335-41.
78. Centers for Disease Control and Prevention. Sexuallytransmitted diseases treatment guidelines, 2006.MMWR Recomm Rep. 2006;55(R-11):1-94.
79. Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvicinflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 1996;334(21):1362-6.
80. Ostergaard L, Andersen B, Moller JK, Olesen F.Home sampling versus conventional swab samplingfor screening ofchlamydia trachomatisin women: acluster-randomized 1-year follow-up study. Clininfect Dis. 2000;31(4):951-7.
81. Oakeshott P, Kerry S, Aghaizu A, et al. Randomisedcontrolled trial of screening forChlamydia trachomatisto prevent pelvic inflammatory disease: thePOPI (prevention of pelvic infection) trial. Bmj.2010;340:c1642.
82. van den Broek IVF, Hoebe CJPA, van Bergen JEAM, et al. Evaluation design of a systematic, selective, internet-based, Chlamydia Screening Implementationin the Netherlands, 2008-2010: implications of firstresults for the analysis. Bmc Infect Dis.2010;10:89.
83. van den Broek IVF, van Bergen JEAM, BrouwersEEHG, et al. Effectiveness of yearly, register basedscreening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation. Bjm 2012;345:e4316.
84. Hocking JS, Spark S, Guy R, et al. The australianchlamydia control effectiveness pilot (ACCEPT):first result from a randomised controlled trail ofannuals chlamydia screening in general practice.Abstracts of the 4th joint BASHH-ASTDA meetingin Brighton, UK. 27-29 June 2012. Sex translmfert2012;88(suppl):A35.
85. Herrmann B, Egger M. Genitalchlamydiatrachomatisinfections in Uppsala County, Sweden,1985-1993: declining rates for how much longer?Sex Transm Dis. 1995;22(4):253-60.
86. Kamwendo F, Forslin L, Bodin L, Danielsson D.Decreasing incidences of gonorrhea- and chlamydia-associated pelvic inflammatory disease: a 25-yearstudy from an urban area of central Sweden. Sextransm Dis. 1996;23(5):384-91.
87. LaMontagne DS, Fenton KA, Pimenta JM, et al.Using chlamydia positivity to estimate prevalence:evidence from the Chlamydia Screening Pilot inEngland. Int J STD AIDS. 2005;16(4):323-7.
88. National Chlamydia Screening Programme. Englandquarters 1-4 April 2010-March 2011. Nationalchlamydia Screening Programme.http://www.chla-mydiascreening.nhs.uk/ps/assets/pdfs/data/sha_pre-sentations11/Q1-4%202010-11%20ENGLAND.pdf. Accessed 20 Oct 2011.
89. Kretzschmar M, Welte R, van Den HA, Postma MJ.Comparative model-based analysis of screening programs forChlamydia trachomatisinfections. Am JEpidemiol. 2001;153(1):90-101.
90. Althaus CL, Heijne JCM, Roellin A, Low N.Transmission dynamics ofChlamydia trachomatisaffect the impact of screening programmes.Epidemics. 2010;2(3):123-31.
91. Regan DG, Wilson DP, Hocking JS. Coverage is the key for effective screening of Chlamydia trachomatis in Australia. J Infect Dis. 2008;198(3):349-58.
92. Turner KME, Adams EJ, LaMontagne DS, EmmettL, Baster K, Edmunds WJ. Modelling the effectiveness of chlamydia screening in England. Sex TransmInfect. 2006;82(6):496-502.
93. Centers for Disease Control and Prevention. Chlamydia trachomatisinfections. Policy guidelines for prevention and control. Mmwr Recomm Rep.1985;34(3):53-74.
94. Centers for Disease Control and Prevention.Infertility Prevention Project.http://www.cdc.gov/std/infertility/ipp.htm. Accessed 6 Sept 2012.
95. U.S. Preventive Services Task Force. Guide to clinical preventive services: an assessment of the effectiveness of 169 preventive interventions. Baltimore:Williams amp; Wilkins; 1989.
96. Centers for Disease Control and Prevention. Sexuallytransmitted diseases treatment guidelines. Mmwrrecomm Rep. 1993;42(RR-14):1-102.
97. Centers for Disease Control and Prevention. Recommendations for the prevention and management ofChlamydia trachomatisinfections, 1993. Mmwr Recomm Rep. 1993;42(12):1-45.
98. Centers for Disease Control and Prevention. Chlamydia trachomatisgenital infections#x2014;United States, 1995. Mmwr Recomm Rep. 1997;46(9):193-8.
99. Mertz KJ, Ransom RL, St Louis ME. Prevalence ofgenital chlamydial infection in young women entering a national job training program, 1990-1997. Amj Public Health. 2001;91(8):1287-90.
100. Centers for Disease Control and Prevention. Divisionof STD prevention. Tracking the hidden epidemics: trends in STDs in the United States, 2000.http://www.cdc.gov/std/Trends2000/trends2000. Pdf.Accessed 6 Sept 2012.
101. Centers for Disease Control and Prevention. Guidelinesfor treatment of sexually transmitted diseases. Mmwrrecomm Rep. 1998;47(1):1-118.
102. Centers for Disease Control and Prevention.Chlamydia screening, HEDIS and managed care.http://www.cdc.gov/std/chlamydia/hedis.htm.Accessed 6 Sept 2012.
103. U.S. Department of Health and Human Services.Midcourse review. Healthy people 2010. Sexuallytransmitted diseases, http://www.healthypeople.gov/2010/Data/midcourse/html/focusareas/FA25TOC.htm. Archive accessed 6 Sept 2012.
104. Nelson HD, Helfand M. Screening for chlamydialinfection. Am J Prev Med. 2001;20 Suppl1:95-107.
105. Centers for Disease Control and Prevention. Sexuallytransmitted diseases treatment guidelines 2002.MMWR Recomm Rep. 2002;51(6):1-78.
106. Centers for Disease Control and Prevention.Expedited partner therapy. Dear Colleague Letter.http://www.cdc.gov/std/DearColleagueEPT5-10-05.pdf. Accessed 6 Sept 2012.
107. Centers for Disease Control and Prevention. Malechlamydia screening. Dear Colleague Letter.http://www.cdc.gov/std/chlamydia/Dear-Colleague-Male-CT-Screening-2007.pdf. Accessed 6 Sept 2012.
108. Association of Public Health Laboratories, Centersfor Disease Control and Prevention. Laboratorydiagnostic testing forChlamydia trachomatisandNeisseria gonorrhoeae:expert consultation meetingsummary report. 13-15 Jan 2009. Atlanta, GA.http://www.aphl.org/aphlprograms/infectious/std/documents/ctgclabguidelinesmeetingreport.pdf.Accessed 6 Sept 2012.
109. Centers for Disease Control and Prevention.Chlamydia screening among sexually active youngfemale enrollees of health plans#x2014;United States,2000-2007. Jama. 2009;302(6):620-1.
110. Communicable Disease Surveillance Centre. Sexuallytransmitted diseases quarterly report: genital infectionwithChlamydia trachomatisin England and Wales.Commun Dis Rep CDR Wkly. 1995;5(26):122-3.
111. Taylor-Robinson D.Chlamydia trachomatisand sexually transmitted disease. Bmj. 1994;308(6922):150-1.
112. Department of Health. First report of the UK National Screening Committee. London: The Stationery Office; 1998.
113. Department of Health. Second report of the NationalScreening Committee. London: The StationeryOffice; 2000.
114. Pimenta JM, Catchpole M, Rogers PA, et al.Opportunistic screening for genital chlamydial infection. I: acceptability of urine testing in primary andsecondary healthcare settings. Sex Transm Infect.2003;79(1): 16-21.
115. Pimenta JM, Catchpole M, Rogers PA, et al.Opportunistic screening for genital chlamydial infection. Ii: prevalence among healthcare attenders, outcome, and evaluation of positive cases. Sex Transm Infect. 2003;79(1):22-7.
116. Department of Health. National strategy for sexualhealth and HIV. London: Department of Health;2001.
117. UK National Screening Committee. Programmedirector#x2019;s report. Period: Autumn 2000-Spring 2002;2002.
118. UK National Screening Committee. Note of themeeting held on 8 Dec 2004; 2004.
119. UK National Screening Committee. Uk ScreeningPortal. Uk NSC policy database. Policies: Chlamydia(adult), Chlamydia (pregnancy).http://www.screen-ing.nhs.uk/policydb.php. Accessed 6 Sept 2012.
120. Adams EJ, Turner KM, Edmunds WJ. The cost effectiveness of opportunistic chlamydia screening inEngland. Sex Transm Infect. 2007;83(4):267-74.
121. Health Protection Agency. National ChlamydiaScreening Programme. The bigger picture. Thenational Chlamydia Screening Programme. 2008/09annual report. London: Health Protection Agency;2009.
122. National Audit Office. Department of Health. Youngpeople#x2019;s sexual health: the National ChlamydiaScreening Programme. Report by the Comptrollerand Auditor General. Hc 963 Session 2008-2009.London: The Stationery Office; 2009. Cancer of the cervix: death by incompetence. Lancet.1985;2(8451):363-4.
123. UK National Screening Committee.http://www.screening.nhs.uk/uknsc. Accessed 6 Sept 2012.
124. Rekart ML, Brunham RC. Epidemiology of chlamydial infection: are we losing ground? Sex TransmInfect. 2008;84(2):87-91.
125. Hennekens CH, DeMets D. Statistical associationand causation. Jama. 2011;305(11):1134-5.
126. Centers for Disease Control and Prevention. Infertilityand prevention of sexually transmitted diseases2000-2003. Report to Congress.http://www.cdc.gov/std/infertility/ipp.htm. Accessed 6 Sept 2012.
127. Soldan K, Berman SM. Danish health register study:a randomised trial with findings about the implementation of chlamydia screening, but not about itsbenefits. Sex Transm Infect. 2011;87(2):86-7.
128. U.S. Department of Health and Human Services.Healthy people 2020. 2011 September.http://www.healthypeople.gov/2020/default.aspx. Accessed6 Sept 2012.
129. Centers for Disease Control and Prevention. Specialfocus: surveillance for sexually transmitted diseases.MMWR Recomm Rep. 1993;42(3):1-39.
130. Peterman TA, Gottlieb SL, Berman SM.Commentary:Chlamydia trachomatisscreening: what are we trying to do? Int J Epidemiol. 2009;38(2):449-51.
131. Tao G, Walsh CM, Anderson LA, Irwin KL.Understanding sexual activity defined in the HEDISmeasure of screening young women forChlamydiatrachomatis.Jt Comm J Qual Improv. 2002;28(8):435-40.
132. Heijne JCM, Tao G, Kent CK, Low N. Uptake ofregular chlamydia testing by U.S. Women: a longitudinal study. Am J Prev Med. 2010;39(3):243-50.
133. National Chlamydia Screening Programme. Nhsvital Signs 2010/11. Primary Care Trust (PCT) andStrategic Health Authority (SHA) specific tables. 1Stapril 2010 to 31st March 2011.http://www.chla-mydiascreening.nhs.uk/ps/assets/pdfs/data/VSI_PCT/VSI_by_PCT_Q 1 -4_April_ 2010-March_2011.pdf. Accessed 6 Sept 2012.
134. Brunham RC, Pourbohloul B, Mak S, White R, Rekart ML. The unexpected impact of aChlamydiatrachomatisinfection control program on susceptibility to reinfection. J Infect Dis. 2005;192(10):1836-44.
135. Hoover K, Tao G. Missed opportunities for chlamydia screening of young women in the UnitedStates. Obstet Gynecol. 2008;111(5):1097-102.
136. Nordin JD, Solberg LI, Parker ED. Adolescentprimary care visit patterns. Ann Fam Med. 2010;8(6):511-6.
137. Nguyen TQ, Ford CA, Kaufman JS, Leone PA, Suchindran C, Miller WC. Infrequent chlamydialtesting among young adults: financial and regionaldifferences. Sex Transm Dis. 2008;35(8):725-30.
138. Geisler WM, Chyu L, Kusunoki Y, Upchurch DM, Hook III EW. Health insurance coverage, healthcare-seeking behaviors, and genital chlamydialinfection prevalence in sexually active young adults.Sex Transm Dis. 2006;33(6):389-96.
139. Sheringham J, Sowden S, Stafford M, Simms I, Raine R. Monitoring inequalities in the NationalChlamydia Screening Programme in England: addedvalue of ACORN, a commercial geodemographicclassification tool. Sex Health. 2009;6(1):57-62.
140. Batteiger BE, Tu W, Ofner S, et al. Repeatedchlamydia trachomatisgenital infections in adolescent women. J Infect Dis. 2010;201(1):42-51.
141. Trelle S, Shang A, Nartey L, Cassell JA, Low N.Improved effectiveness of partner notification forpatients with sexually transmitted infections: systematic review. Bmj. 2007;334(7589):354-7.
142. Estcourt C, Sutcliffe L. Moving partner noti fi cationinto the mainstream of routine sexual health care.Sex Transm Infect. 2007;83(2):169-72.
143. Ostergaard L, Andersen B, Olesen F, Moller JK.Efficacy of home sampling for screening ofChlamydia trachomatis:randomised study. Bmj.1998;317(7150):26-7.
144. Macleod J, Salisbury C, Low N, et al. Coverage anduptake of systematic postal screening for genitalChlamydia trachomatisand prevalence of infectionin the United Kingdom general population: crosssectional study. Bmj. 2005;330(7497):940-2.
145. Scott LaMontagne D, Baster K, Emmett L, et al.Incidence and reinfection rates of genital chlamydialinfection among women aged 16-24 years attendinggeneral practice, family planning and genitourinarymedicine clinics in England: a prospective cohortstudy by the Chlamydia Recall Study AdvisoryGroup. Sex Transm Infect. 2007;83(4):292-303.
146. Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Prioritiesamong effective clinical preventive services: resultsof a systematic review and analysis. Am J Prev Med.2006;31(1):52-61.
147. Brandt AM. No magic bullet: a social history of venereal disease in the United States since 1880. 2Nd ed.New York: Oxford University Press, Inc.; 1985.
148. Cowan FM, Plummer M. Biological, behaviouraland psychological outcome measures. In: StephensonJM, Imrie J, Bonell C, editors. Effective sexualhealth interventions. Issues in experimental evaluation. Oxford: Oxford University Press; 2003.p. 111-35.
149. Nadala EC, Goh BT, Magbanua JP, et al. Performanceevaluation of a new rapid urine test for chlamydia inmen: prospective cohort study. Bmj. 2009;339:b2655.
150. Gaydos CA, Dwyer K, Barnes M, et al. Internet-based screening forChlamydia trachomatisto reachnon-clinic populations with mailed self-administeredvaginal swabs. Sex Transm Dis. 2006;33(7):451-7.
151. Gottlieb SL, Martin D, Xu F, et al. Summary: the natural history and immunobiology ofChlamydia trachomatisgenital infection and implications for chlamydiacontrol. J Infect Dis. 2010;201(2):190-204.
152. Darville T, Hiltke TJ. Pathogenesis of genital tractdisease due toChlamydia trachomatis. J Infect Dis.2010;201(2):114-25.